An interventional study of Groningen Anti-Inflammatory Diet (GrAID) and ColoVit capsule in Crohn Disease, sponsored by University Medical Center Groningen. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-14.
Sponsored by University Medical Center Groningen · Not applicable, Interventional, and Treatment
This study will evaluate if the Groningen Anti-Inflammatory Diet and the ileocolonic delivery of vitamin B2, B3 and C can positively influence the course of Crohn's disease and can positively alter the gut microbiome of Crohn's disease patients as well as healthy volunteers.
It is becoming increasingly more well known that diet and the microbiome have a pivotal role in the development and course of inflammatory bowel diseases (IBD). Strict exclusive enteral nutrition (EEN) can induce remission in Crohn's Disease (CD) and is the standard treatment in paediatric CD. Implementing a restrictive diet in adults is difficult; adult patients do not tend to adhere to EEN. Recently, the CD-exclusion diet (CDED) combined with partial enteral nutrition demonstrated to be effective in CD-patients with flares.
Additionally, accumulating evidence suggests that intake of vitamins can influence disease course, mainly by beneficially modulating the gut microbiota and gut redox potential, especially if the vitamins can be delivered to the colon.
Nevertheless, no dietary guidelines are available to physicians and patients. Due to complaints of certain foods and patients' eagerness to postpone new flares, patients start experimenting with their food. As patients with CD are already often malnourished, this poorly substantiated experimenting puts them even more at risk for malnutrition and could have a potential negative effect on their disease outcomes. Next, quality of life of patients decreases and healthcare costs will rise. Therefore, both patients and physicians are in desperate need of evidence for an anti-inflammatory dietary advice in CD. As compliance to a diet increases when they are supported by family members, their household members will also be asked to participate in the study. Simultaneously studying their healthy family members will also provide information of the effect of this anti-inflammatory diet or intake of lieocolonic-delivered vitamins on their microbiome and markers of inflammation and oxidative stress.
1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.
This study's planned enrollment of 510 is above the median of 66 across 1,188 interventional studies indexed under Crohn Disease.
Browse Crohn Disease studies →University Medical Center Groningen is the lead sponsor of 609 studies on the registry; 174 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria CD patients:
Inclusion Criteria healthy volunteers:
Exclusion Criteria CD patients:
Exclusion Criteria healthy subjects:
Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups.
Other: Groningen Anti-Inflammatory Diet (GrAID)
2 times daily intake of a supplement containing 37,5 mg vitamin B2, 2,5 mg vitamin B3 and 250 mg vitamin C in a ColoPulse-coated capsule, a pH-sensitive coating allowing ileocolonic-targeted-delivery
Dietary Supplement: ColoVit capsule
2 times daily intake of a capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit
Other: ColoPulse-placebo capsule
Specially designed diet based on the most recent scientific evidence of the inflammatory characteristics of food and food groups. Basically, subjects will be instructed to increase uptake of food components that hold potential anti-inflammatory proportions and to avoid food components that may showcase potential pro-inflammatory proportions.
Vitamin B2/B3/C supplement in a ColoPulse-coated capsule
A capsule containing microcrystalline cellulose which is coated using the same ColoPulse technology as is used with the ColoVit
Change in faecal calprotectin
Primary outcome for CD patients
Time frame: Faeces sample collection at 4 time points: At baseline (0 months), after 3 months, after 6 months, after 12 months
Change in microbiome composition measured by metagenomic sequencing- based profiles
Primary outcome for healthy volunteers and CD patients
Time frame: Faeces sample collection at 3 time points: At baseline (0 months), after 3 months, after 12 months
The number of flares (defined as faecal calprotectin >200 μg/g and Crohn's Disease Activity Index (CDAI) ≥220 points)
Secondary outcome for CD patients
Time frame: Faeces sample collection and CDAI score determination at 4 time points: At baseline (0 months), after 3 months, after 6 months, after 12 months
Improvements of Quality of life scores as assessed by Inflammatory Bowel Disease Questionnaire (Score range of 32-224, The higher the score the higher the Quality of Life)
Secondary outcome for CD patients
Time frame: Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months
Improvements of Quality of life scores as assessed Food Related Quality of Life Questionnaire (Score range of 29-145, The higher the score the higher the Food related-Quality of Life)
Secondary outcome for CD patients and healthy volunteers
Time frame: Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months
Adherence to the dietary interventions as assessed by a Dietary Compliance Questionnaire
Secondary outcome for CD patients and healthy volunteers
Time frame: Questionnaires at 3 time points: At baseline (0 months), after 3 months, after 12 months
Plan to share: No — There is no plan to make individual participant data available to other researchers outside of the study team.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen